With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Role of PHF6 Mutations in Germline RUNX1 Deficiency Associated Hematopoietic Disorders||Boston Children's Hospital / Serine Avagyan, MD/PhD||RUNX1 Early Career Investigator Grants||2021||Massachusetts|
|Characterizing Inflammatory Phenotypes Associated with RUNX1 Deficiency||Dana-Farber Cancer Institute / Waihay Wong, MD/PhD||RUNX1 Early Career Investigator Grants||2021||Massachusetts|
|Dissecting Functional uORFs as a Source of Cancer Genes in High-Risk Medulloblastoma||Dana-Farber Cancer Institute / John Prensner, MD/PhD||Young Investigator Grants||2021||Massachusetts|
|Dissecting the Contribution and Inheritance of Germline DNA Damage Repair Gene Mutations in Neuroblastoma||Dana-Farber Cancer Institute / Riaz Gillani, MD||Young Investigator Grants||2021||Massachusetts|
|Choline Kinase and Alkylating Agent Resistance in Refractory Childhood Leukemias||Boston Children's Hospital / Alejandro Gutierrez, MD||Innovation Grants||2021||Massachusetts|
|Hematopoietic stem cell function in familial platelet disorder therapy||University of Massachusetts Medical School / Lucio Castilla, PhD||Innovation Grants||2021||Massachusetts|
|Unraveling metabolic dependencies in childhood supratentorial ependymomas.||Regents of the University of Michigan / Sriram Venneti, MD/PhD||Innovation Grants||2021||Michigan|
|Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG||Mayo Clinic / David Daniels, MD/PhD||Reach Grants||2021||Minnesota|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|